Choroidal Changes During and After Discontinuing Long-Term 0.01% Atropine Treatment for Myopia Control
Open Access
- 1 August 2024
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 65 (10) , 21
Abstract
Purpose: Few studies have explored choroidal changes after cessation of myopia control. This study evaluated the choroidal thickness (ChT) and choroidal vascularity index (CVI) during and after discontinuing long-term low-concentration atropine eye drops use for myopia control. Methods: Children with progressive myopia (6–16 years; n = 153) were randomized to receive 0.01% atropine eye drops or a placebo (2:1 ratio) instilled daily over 2 years, followed by a 1-year washout (no eye drop use). Optical coherence tomography imaging of the choroid was conducted at the baseline, 2-year (end of treatment phase), and 3-year (end of washout phase) visits. The main outcome measure was the subfoveal ChT. Secondary measures include the CVI. Results: During the treatment phase, the subfoveal choroids in both treatment and control groups thickened by 12–14 µm (group difference P = 0.56). During the washout phase, the subfoveal choroids in the placebo group continued to thicken by 6.6 µm (95% confidence interval [CI] = 1.7 to 11.6), but those in the atropine group did not change (estimate = -0.04 µm; 95% CI = –3.2 to 3.1). Participants with good axial eye growth control had greater choroidal thickening than the fast-progressors during the treatment phase regardless of the treatment group (P < 0.001), but choroidal thickening in the atropine group's fast-progressors was not sustained after stopping eye drops. CVI decreased in both groups during the treatment phase, but increased in the placebo group after treatment cessation. Conclusions: On average, compared to placebo, 0.01% atropine eye drop treatment did not cause a differential rate of change in ChT during treatment, but abrupt cessation of long-term 0.01% atropine eye drops may disrupt normal choroidal thickening in children.Keywords
This publication has 34 references indexed in Scilit:
- The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) StudyAmerican Journal of Ophthalmology, 2022
- Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus WashoutOphthalmology, 2022
- Choroidal thickness and ocular growth in childhoodSurvey of Ophthalmology, 2021
- Intention-to-treat analysis when only a baseline value is availableContemporary Clinical Trials Communications, 2020
- Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopiaScientific Reports, 2020
- Changes in Choroidal Thickness Varied by Age and Refraction in Children and Adolescents: A 1-Year Longitudinal StudyAmerican Journal of Ophthalmology, 2020
- Automatic choroidal segmentation in OCT images using supervised deep learning methodsScientific Reports, 2019
- The effect of topical atropine on the choroidal thickness of healthy childrenScientific Reports, 2016
- Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%American Journal of Ophthalmology, 2014
- The multifunctional choroidProgress in Retinal and Eye Research, 2010